Press Release
Xintela AB (publ)
556780-3480
2016-04-25 08.30

Xintela initiates a study on the treatment of cartilage damage in horses in the USA.

Xintela AB (publ) announces today that the company have initiated a study, in the USA, on the treatment of cartilage damage in horses. The study is being conducted in collaboration with an eminent research group at Cornell Univesity. Xintela's stem cells have been injected into horse joints and the study is expected to be completed by the end of the year. The purpose of the study is, in part, to determine that stem cells are safe to use and, in part, to examine if they can improve joint function.

– We are very happy that the study has started and we are excitedly awaiting the results, which are expected at the end of the year. We are also excited that we have now initiated a collaboration with a research group at Cornell University who are renowned in the field of veterinary medicine and orthopaedic diseases, with a special focus in, amongst others, regenerative medicine, says Evy Lundgren-Åkerlund, CEO at Xintela.

Xintela's marker technology has been used to isolate so-called mesenchymal stem cells from adipose tissue from a horse donor and to select the correct type of stem cells to use in the horse study. Xintela's laboratory research has shown that those stem cells, which the company's patented markers select, have the ability to develop into cartilage-producing cells. At the end of March, Xintela sent the stem cells to Cornell University and the first stem cells have now been injected into horse joints, with damaged cartilage.

The goal of the study is primarily to determine if Xintela's stem cells are safe to use and are tolerated well by the horse under treatment. The study will also examine if stem cells have the ability to improve joint function, determined by examining lameness (a sign of pain) and regeneration of cartilage tissue.

– The results of the study are important in our continued ambition to develop a stem cell product for horses but also to prepare for clinical studies in man, since the horse is an excellent animal model for human conditions, says Evy Lundgren-Åkerlund.

About the study
The study, which is being conducted in collaboration with Cornell University, comprises eight horses. Horses, with damaged cartilage in joints, that are equivalent to the ankles in humans, have stem cells injected into one joint and a saline solution into the other joint. During the study, any possible reaction to the stem cells will be investigated, as will the effect of the stem cells on lameness and joint mobility as a measure of joint function. Multiple analyses of joint fluid, cells and tissues will also be conducted. The study is expected to be completed by the end of the year.

About Xintela
Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours. The Company was founded in 2009, but research and development started in 2013. The key to Xintela's business is the Company's patented marker technology, XINMARK™. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces. The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK™-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Consensus Asset Management AB.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46-70-329 18 71
E-mail: evy@xintela.se

Press Release
Xintela AB (publ)
556780-3480
2016-04-25 08.30

Medicon Village
223 81 Lund, Sweden
www.xintela.se

Any questions on trade in Xintela's shares and options will be answered by the Company's Certified Adviser, Consensus Asset Management AB. Telephone: +46-31-745 50 00.

Media and Investor Relations related questions should be directed to:
Adam Lindblom, Laika Consulting
Tel: +46 -73-062 20 13
E-mail: adam.lindblom@laika.se
www.laika.se

Information released for public consumption April 25 2016, 08.30 CET